Expression of SALL4,GS and HSP70 in hepatocellular carcinoma tissues and its clinical value in early screening
Objective To analyze the expression of brachystegia-like gene 4 (SALL4,SALL4),glutamine synthase (GS),heat shock protein 70 (HSP70) in hepatocellular carcinoma tissues and their clinical value in early screening.Methods A total of 153 patients with primary liver cancer treated at Santai County People's Hospital from July 2020 to June 2023 were selected for the study.The liver cancer group included 58 cases of grade Ⅰ～Ⅱ and 95 cases of grade Ⅲ～Ⅳ based on the Edmondson pathological grade.Additionally,153 cases of paracarcinoma tissues located more than 3 cm away from the tumor margin were used as the control group,and 141 cases of benign liver disease tissues were used as the benign group.The aim of the study was to analyze the expression of SALL4 protein,GS,and HSP70 in patients with different grades within the three groups,as well as in the hepatocellular carcinoma group.The goal was to determine the value of SALL4 protein,GS,and HSP70 for the early diagnosis of hepatocellular carcinoma.Results The positive expression rates of the SALL4 gene,GS,and HSP70 in different tissues were as follows:liver cancer group>benign group>control group.The difference was statistically significant (P<0.05).The positive rates of the SALL4 gene,GS,and HSP70 in grade Ⅲ～Ⅳ patients were significantly higher than those in grade Ⅰ～Ⅱ,with statistically significant differences (P<0.05).Based on the ROC curve,it is evident that the sensitivity and specificity of the SALL4+GS+HSP70 combined test for the early diagnosis of hepatocellular carcinoma were 95.10％ and 78.60％,respectively,with an AUC of 0.838 (95％ CI:0.755-0.922).This was significantly higher than that of SALL4,GS,and HSP70 alone (P<0.05).Conclusions The SALL4 protein,GS,and HSP70 are highly expressed in liver cancer tissues.The expression of all three may be used as an assessment indicator for early screening of liver cancer.This has important clinical significance in the early diagnosis and disease assessment of liver cancer.
万方数据
维普
